Loading stock data…
$10.19
Drugs Made In America Acquisition II Corp.
Drugs Made In America Acquisition II Corp. in the Financial Services sector is trading at $10.19 with a market capitalization of $647M. The stock is currently 1% below its 52-week high of $10.33, remaining 1.4% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$112,227↓ | -$102,030↑ | -$1.05M↓ | -$155,513↓ | -$38,073 |
| Net Income | $4.40M↑ | $4.34M↑ | $4.33M↑ | -$46,158↓ | -$38,073 |
Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination wit...